Glucosio S.A.L.F

Glucosio S.A.L.F is a sterile solution for injection that contains glucose monohydrate as its sole active ingredient. The product is supplied in an unspecified strength and is manufactured for the European Union market. As an intravenous carbohydrate source, it is classified as an excipient and nutritional supplement, providing caloric energy when administered under clinical supervision. It is used by healthcare professionals to maintain blood glucose levels during procedures.

Glucosio S.A.L.F is employed in clinical practice where rapid provision of carbohydrate calories is needed.

- Intravenous supplementation of glucose during surgical or diagnostic procedures to maintain energy balance. - Temporary support for patients who cannot tolerate oral intake, such as those on fasting protocols. - Adjunctive therapy for medically supervised correction of low blood glucose levels (hypoglycemia). - Component of short‑term parenteral nutrition formulations providing readily available carbohydrate calories. - Reference solution for laboratory calibration of glucose measurement devices and quality‑control testing.

When administered intravenously, Glucosio S.A.L.F may be associated with a range of observed effects, most of which are related to its glucose content.

Common: - Transient increase in blood glucose concentration. - Mild hyperosmolarity leading to temporary thirst. - Local irritation at the injection site. - Nausea or mild gastrointestinal discomfort. - Transient headache related to rapid glucose infusion.

Serious: - Severe hyperglycemia with potential osmotic diuresis. - Electrolyte imbalance, particularly hyponatremia. - Allergic or anaphylactic reaction to formulation components. - Volume overload in patients with compromised cardiac function. - Metabolic acidosis in patients with impaired lactate clearance. - Severe hypoglycemia rebound after abrupt discontinuation.

Healthcare providers should observe specific precautions when using Glucosio S.A.L.F to ensure patient safety and optimal therapeutic outcomes.

- Verify patient’s baseline blood glucose and electrolyte status before infusion. - Adjust infusion rate in patients with diabetes or impaired glucose tolerance. - Use caution in individuals with renal or hepatic dysfunction due to altered glucose metabolism. - Monitor for signs of fluid overload, especially in cardiac or pulmonary disease. - Avoid rapid bolus administration; prefer controlled infusion to reduce osmotic shifts. - Ensure aseptic technique to prevent catheter‑related infections. - Document infusion details in the patient’s medical record.

Glucosio S.A.L.F can interact with other agents administered intravenously; awareness of these interactions helps prevent adverse events.

Avoid: - Concurrent rapid infusion of other hyperosmolar solutions (e.g., mannitol) that may exacerbate fluid shifts. - Co‑administration with high‑dose insulin without appropriate glucose monitoring. - Concurrent administration with other carbohydrate‑containing infusions, which may cause excessive hyperglycemia.

Use with caution: - Simultaneous use of diuretics that may alter electrolyte balance. - Concurrent administration of calcium‑containing solutions, which can affect calcium‑glucose complex formation. - Use alongside catecholamines, as they may influence glucose metabolism. - Combination with blood products that contain citrate, potentially affecting calcium levels. - Patients receiving glucocorticoids, as they may increase glucose production and require closer monitoring. - Administration with other parenteral nutrition components, requiring careful monitoring of total carbohydrate load.